{"transactions":[{"id":744310,"issuer":{"id":5797,"kind":"organization","name":"SUTRO BIOPHARMA, INC.","symbol":"STRO"},"owners":[{"id":39979,"kind":"person","name":"Jagpal Sukhi","position":1,"cik":"0001554591","reported_name":"Jagpal Sukhi","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-09T20:18:09.000Z","date":"2026-06-05","kind":"grant","planned":false,"acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shall vest, subject to the reporting person's provision of service to the issuer on each vesting date, as to 8.33% of the total award monthly, with the first tranche vesting on July 5, 2026, and the award shall be fully vested and exercisable on the earlier of (i) the date of the issuer's 2027 annual stockholders meeting or (ii) June 5, 2027."}],"balance_after":10000,"derivative":{"exercise_price":26.09,"expiration_date":"2036-06-05","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001554591-26-000002","document":"form4-06092026_080605.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1382101/000155459126000002/form4-06092026_080605.xml","form_type":"4"}},{"id":957985,"issuer":{"id":5797,"kind":"organization","name":"SUTRO BIOPHARMA, INC.","symbol":"STRO"},"owners":[{"id":39979,"kind":"person","name":"Jagpal Sukhi","position":1,"cik":"0001554591","reported_name":"Jagpal Sukhi","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-12-29T21:58:48.000Z","date":"2025-12-23","kind":"grant","planned":false,"acquired":true,"shares":1500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shall vest as to 16.67% of the total award monthly, subject to the reporting person's continued service to the issuer on each vesting date, with the first tranche vesting on January 23, 2026."}],"balance_after":1500,"derivative":{"exercise_price":10.38,"expiration_date":"2035-12-23","underlying":"Common Stock","underlying_shares":1500},"source":{"system":"sec-edgar","filing":"0001554591-25-000004","document":"form4-12292025_091244.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1382101/000155459125000004/form4-12292025_091244.xml","form_type":"4"}},{"id":1116048,"issuer":{"id":5797,"kind":"organization","name":"SUTRO BIOPHARMA, INC.","symbol":"STRO"},"owners":[{"id":39979,"kind":"person","name":"Jagpal Sukhi","position":1,"cik":"0001554591","reported_name":"Jagpal Sukhi","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-10T20:10:33.000Z","date":"2025-06-06","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 8.33% of the total shares monthly, commencing July 6, 2025, with 100% of the total shares vested and exercisable on the earlier of the date of the issuer's 2026 annual stockholders meeting or June 6, 2026, subject to the reporting person's provision of service to the issuer on each vesting date."}],"balance_after":50000,"derivative":{"exercise_price":0.85,"expiration_date":"2035-06-06","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001415889-25-016466","document":"form4-06102025_080630.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1382101/000141588925016466/form4-06102025_080630.xml","form_type":"4"}},{"id":1435801,"issuer":{"id":5797,"kind":"organization","name":"SUTRO BIOPHARMA, INC.","symbol":"STRO"},"owners":[{"id":39979,"kind":"person","name":"Jagpal Sukhi","position":1,"cik":"0001554591","reported_name":"Jagpal Sukhi","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-08-12T20:40:20.000Z","date":"2024-08-08","kind":"grant","planned":false,"acquired":true,"shares":28959,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests as to 10.07% of the total award monthly beginning on September 8, 2024 through May 8, 2025, and 9.38% shall vest on June 6, 2025, with 100% of the award being vested and exercisable on the date of the issuer's 2025 annual meeting of its stockholders, subject to the reporting person's provision of service to the issuer on each vesting date."}],"balance_after":28959,"derivative":{"exercise_price":3.22,"expiration_date":"2034-08-08","underlying":"Common Stock","underlying_shares":28959},"source":{"system":"sec-edgar","filing":"0001415889-24-021089","document":"form4-08122024_080817.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1382101/000141588924021089/form4-08122024_080817.xml","form_type":"4"}},{"id":1435800,"issuer":{"id":5797,"kind":"organization","name":"SUTRO BIOPHARMA, INC.","symbol":"STRO"},"owners":[{"id":39979,"kind":"person","name":"Jagpal Sukhi","position":1,"cik":"0001554591","reported_name":"Jagpal Sukhi","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-08-12T20:40:20.000Z","date":"2024-08-08","kind":"grant","planned":false,"acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 2.778% of the total award monthly, beginning on September 8, 2024, with 100% of the award being vested and exercisable on August 8, 2027, subject to the reporting person's provision of service to the issuer on each vesting date."}],"balance_after":35000,"derivative":{"exercise_price":3.22,"expiration_date":"2034-08-08","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001415889-24-021089","document":"form4-08122024_080817.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1382101/000141588924021089/form4-08122024_080817.xml","form_type":"4"}},{"id":2216997,"issuer":{"id":125698,"kind":"organization","name":"Sierra Oncology, Inc.","symbol":"SRRA"},"owners":[{"id":39979,"kind":"person","name":"Jagpal Sukhi","position":1,"cik":"0001554591","reported_name":"Jagpal Sukhi","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2022-07-01T16:42:46.000Z","date":"2022-07-01","kind":"disposition_to_issuer","acquired":false,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F9","text":"Pursuant to the terms of the merger agreement between issuer, GSK and a subsidiary of GSK, this option was cancelled on the effective date of the merger in exchange for a cash payment equal to, on a per share basis, the offer price of $55.00 less the exercise price."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F13","text":"The option vests as to 25% of the total shares subject to the option on March 14, 2023, and then 2.0833% of the shares subject to the option vest monthly thereafter, with 100% of the total shares subject to the option vested on March 14, 2026, subject to Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":0,"derivative":{"exercise_price":31.54,"expiration_date":"2032-03-14","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001209191-22-040271","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1290149/000120919122040271/doc4.xml","form_type":"4"}},{"id":2216996,"issuer":{"id":125698,"kind":"organization","name":"Sierra Oncology, Inc.","symbol":"SRRA"},"owners":[{"id":39979,"kind":"person","name":"Jagpal Sukhi","position":1,"cik":"0001554591","reported_name":"Jagpal Sukhi","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2022-07-01T16:42:46.000Z","date":"2022-07-01","kind":"disposition_to_issuer","acquired":false,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F9","text":"Pursuant to the terms of the merger agreement between issuer, GSK and a subsidiary of GSK, this option was cancelled on the effective date of the merger in exchange for a cash payment equal to, on a per share basis, the offer price of $55.00 less the exercise price."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F12","text":"The option vested as to 25% of the total shares subject to the option on March 15, 2022, and then 2.0833% of the shares subject to the option vest monthly thereafter, with 100% of the total shares subject to the option vested on March 15, 2025, subject to Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":0,"derivative":{"exercise_price":16.73,"expiration_date":"2031-03-15","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001209191-22-040271","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1290149/000120919122040271/doc4.xml","form_type":"4"}},{"id":2216995,"issuer":{"id":125698,"kind":"organization","name":"Sierra Oncology, Inc.","symbol":"SRRA"},"owners":[{"id":39979,"kind":"person","name":"Jagpal Sukhi","position":1,"cik":"0001554591","reported_name":"Jagpal Sukhi","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2022-07-01T16:42:46.000Z","date":"2022-07-01","kind":"disposition_to_issuer","acquired":false,"shares":5887,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F9","text":"Pursuant to the terms of the merger agreement between issuer, GSK and a subsidiary of GSK, this option was cancelled on the effective date of the merger in exchange for a cash payment equal to, on a per share basis, the offer price of $55.00 less the exercise price."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F11","text":"The option vested as to 25% of the total shares on August 10, 2021, and then 2.0833% of the total shares vest monthly thereafter, with 100% of the total shares vested on August 10, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":0,"derivative":{"exercise_price":12.15,"expiration_date":"2030-08-12","underlying":"Common Stock","underlying_shares":5887},"source":{"system":"sec-edgar","filing":"0001209191-22-040271","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1290149/000120919122040271/doc4.xml","form_type":"4"}},{"id":2216994,"issuer":{"id":125698,"kind":"organization","name":"Sierra Oncology, Inc.","symbol":"SRRA"},"owners":[{"id":39979,"kind":"person","name":"Jagpal Sukhi","position":1,"cik":"0001554591","reported_name":"Jagpal Sukhi","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2022-07-01T16:42:46.000Z","date":"2022-07-01","kind":"disposition_to_issuer","acquired":false,"shares":49000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F9","text":"Pursuant to the terms of the merger agreement between issuer, GSK and a subsidiary of GSK, this option was cancelled on the effective date of the merger in exchange for a cash payment equal to, on a per share basis, the offer price of $55.00 less the exercise price."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"On August 12, 2020, the Reporting Person was granted an option to purchase 49,000 shares of common stock. The option vests based on the satisfaction by Issuer of certain performance criteria."}],"balance_after":0,"derivative":{"exercise_price":12.15,"expiration_date":"2030-08-12","underlying":"Common Stock","underlying_shares":49000},"source":{"system":"sec-edgar","filing":"0001209191-22-040271","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1290149/000120919122040271/doc4.xml","form_type":"4"}},{"id":2216993,"issuer":{"id":125698,"kind":"organization","name":"Sierra Oncology, Inc.","symbol":"SRRA"},"owners":[{"id":39979,"kind":"person","name":"Jagpal Sukhi","position":1,"cik":"0001554591","reported_name":"Jagpal Sukhi","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2022-07-01T16:42:46.000Z","date":"2022-07-01","kind":"disposition_to_issuer","acquired":false,"shares":94113,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F9","text":"Pursuant to the terms of the merger agreement between issuer, GSK and a subsidiary of GSK, this option was cancelled on the effective date of the merger in exchange for a cash payment equal to, on a per share basis, the offer price of $55.00 less the exercise price."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The option vested as to 25% of the total shares on February 25, 2021, and then 2.0833% of the total shares vest monthly thereafter, with 100% of the total shares vested on February 25, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":0,"derivative":{"exercise_price":13.31,"expiration_date":"2030-02-25","underlying":"Common Stock","underlying_shares":94113},"source":{"system":"sec-edgar","filing":"0001209191-22-040271","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1290149/000120919122040271/doc4.xml","form_type":"4"}},{"id":2216992,"issuer":{"id":125698,"kind":"organization","name":"Sierra Oncology, Inc.","symbol":"SRRA"},"owners":[{"id":39979,"kind":"person","name":"Jagpal Sukhi","position":1,"cik":"0001554591","reported_name":"Jagpal Sukhi","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2022-07-01T16:42:46.000Z","date":"2022-07-01","kind":"disposition_to_issuer","acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the merger agreement between issuer, GlaxoSmithKline plc (\"GSK\") and a subsidiary of GSK, this option was cancelled on the effective date of the merger."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The option vested as to 25% of the total shares on January 1, 2020, and then 2.0833% of the total shares vest monthly thereafter, with 100% of the total shares vested on January 1, 2023, subject to the reporting person's provision of service to the issuer on each vesting date."}],"balance_after":0,"derivative":{"exercise_price":78.4,"expiration_date":"2029-03-04","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001209191-22-040271","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1290149/000120919122040271/doc4.xml","form_type":"4"}},{"id":2216991,"issuer":{"id":125698,"kind":"organization","name":"Sierra Oncology, Inc.","symbol":"SRRA"},"owners":[{"id":39979,"kind":"person","name":"Jagpal Sukhi","position":1,"cik":"0001554591","reported_name":"Jagpal Sukhi","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2022-07-01T16:42:46.000Z","date":"2022-07-01","kind":"disposition_to_issuer","acquired":false,"shares":4509,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the merger agreement between issuer, GlaxoSmithKline plc (\"GSK\") and a subsidiary of GSK, this option was cancelled on the effective date of the merger."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The option fully vested on January 1, 2022."}],"balance_after":0,"derivative":{"exercise_price":94.4,"expiration_date":"2028-03-06","underlying":"Common Stock","underlying_shares":4509},"source":{"system":"sec-edgar","filing":"0001209191-22-040271","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1290149/000120919122040271/doc4.xml","form_type":"4"}},{"id":2216990,"issuer":{"id":125698,"kind":"organization","name":"Sierra Oncology, Inc.","symbol":"SRRA"},"owners":[{"id":39979,"kind":"person","name":"Jagpal Sukhi","position":1,"cik":"0001554591","reported_name":"Jagpal Sukhi","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2022-07-01T16:42:46.000Z","date":"2022-07-01","kind":"disposition_to_issuer","acquired":false,"shares":1750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the merger agreement between issuer, GlaxoSmithKline plc (\"GSK\") and a subsidiary of GSK, this option was cancelled on the effective date of the merger."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The option fully vested on January 1, 2021."}],"balance_after":0,"derivative":{"exercise_price":58,"expiration_date":"2027-03-06","underlying":"Common Stock","underlying_shares":1750},"source":{"system":"sec-edgar","filing":"0001209191-22-040271","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1290149/000120919122040271/doc4.xml","form_type":"4"}},{"id":2216989,"issuer":{"id":125698,"kind":"organization","name":"Sierra Oncology, Inc.","symbol":"SRRA"},"owners":[{"id":39979,"kind":"person","name":"Jagpal Sukhi","position":1,"cik":"0001554591","reported_name":"Jagpal Sukhi","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2022-07-01T16:42:46.000Z","date":"2022-07-01","kind":"disposition_to_issuer","acquired":false,"shares":4200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the merger agreement between issuer, GlaxoSmithKline plc (\"GSK\") and a subsidiary of GSK, this option was cancelled on the effective date of the merger."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option fully vested on September 30, 2019."}],"balance_after":0,"derivative":{"exercise_price":72.8,"expiration_date":"2026-09-30","underlying":"Common Stock","underlying_shares":4200},"source":{"system":"sec-edgar","filing":"0001209191-22-040271","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1290149/000120919122040271/doc4.xml","form_type":"4"}},{"id":2216988,"issuer":{"id":125698,"kind":"organization","name":"Sierra Oncology, Inc.","symbol":"SRRA"},"owners":[{"id":39979,"kind":"person","name":"Jagpal Sukhi","position":1,"cik":"0001554591","reported_name":"Jagpal Sukhi","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2022-07-01T16:42:46.000Z","date":"2022-07-01","kind":"disposition_to_issuer","acquired":false,"shares":1218,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the merger agreement between issuer, GlaxoSmithKline plc (\"GSK\") and a subsidiary of GSK, this option was cancelled on the effective date of the merger."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option fully vested on January 1, 2020."}],"balance_after":0,"derivative":{"exercise_price":263.2,"expiration_date":"2026-03-08","underlying":"Common Stock","underlying_shares":1218},"source":{"system":"sec-edgar","filing":"0001209191-22-040271","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1290149/000120919122040271/doc4.xml","form_type":"4"}},{"id":2216987,"issuer":{"id":125698,"kind":"organization","name":"Sierra Oncology, Inc.","symbol":"SRRA"},"owners":[{"id":39979,"kind":"person","name":"Jagpal Sukhi","position":1,"cik":"0001554591","reported_name":"Jagpal Sukhi","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2022-07-01T16:42:46.000Z","date":"2022-07-01","kind":"disposition_to_issuer","acquired":false,"shares":3859,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the merger agreement between issuer, GlaxoSmithKline plc (\"GSK\") and a subsidiary of GSK, this option was cancelled on the effective date of the merger."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option fully vested on February 2, 2019."}],"balance_after":0,"derivative":{"exercise_price":122.2,"expiration_date":"2025-03-18","underlying":"Common Stock","underlying_shares":3859},"source":{"system":"sec-edgar","filing":"0001209191-22-040271","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1290149/000120919122040271/doc4.xml","form_type":"4"}},{"id":2227406,"issuer":{"id":125698,"kind":"organization","name":"Sierra Oncology, Inc.","symbol":"SRRA"},"owners":[{"id":39979,"kind":"person","name":"Jagpal Sukhi","position":1,"cik":"0001554591","reported_name":"Jagpal Sukhi","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-17T16:12:28.000Z","date":"2022-06-17","kind":"grant","acquired":true,"shares":12250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On August 12, 2020, the reporting person was granted an option to purchase 49,000 shares of common stock. The option vests based on the satisfaction by Issuer of certain performance criteria. The achievement of one of the performance criteria resulted in vesting of the option as to 12,250 shares."}],"balance_after":12250,"derivative":{"exercise_price":12.15,"exercise_date":"2022-06-17","expiration_date":"2030-08-12","underlying":"Common Stock","underlying_shares":12250},"source":{"system":"sec-edgar","filing":"0001209191-22-037841","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1290149/000120919122037841/doc4.xml","form_type":"4"}},{"id":2335223,"issuer":{"id":125698,"kind":"organization","name":"Sierra Oncology, Inc.","symbol":"SRRA"},"owners":[{"id":39979,"kind":"person","name":"Jagpal Sukhi","position":1,"cik":"0001554591","reported_name":"Jagpal Sukhi","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-03-14T16:47:23.000Z","date":"2022-03-14","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 25% of the total shares subject to the option on March 14, 2023, and then 2.0833% of the shares subject to the option vest monthly\nthereafter, with 100% of the total shares subject to the option vested on March 14, 2026, subject to Reporting Person's provision of service to the Issuer on\neach vesting date."}],"balance_after":50000,"derivative":{"exercise_price":31.54,"expiration_date":"2032-03-14","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001209191-22-018490","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1290149/000120919122018490/doc4.xml","form_type":"4"}},{"id":2422350,"issuer":{"id":125698,"kind":"organization","name":"Sierra Oncology, Inc.","symbol":"SRRA"},"owners":[{"id":39979,"kind":"person","name":"Jagpal Sukhi","position":1,"cik":"0001554591","reported_name":"Jagpal Sukhi","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-01-28T18:31:20.000Z","date":"2022-01-28","kind":"grant","acquired":true,"shares":12250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On August 12, 2020, the Reporting Person was granted an option to purchase 49,000 shares of common stock. The option vests based on the satisfaction by Issuer of certain performance criteria. The achievement of one of the performance criteria resulted in vesting of the option as to 12,250 shares."}],"balance_after":12250,"derivative":{"exercise_price":12.15,"exercise_date":"2022-01-28","expiration_date":"2030-08-12","underlying":"Common Stock","underlying_shares":12250},"source":{"system":"sec-edgar","filing":"0001209191-22-005480","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1290149/000120919122005480/doc4.xml","form_type":"4"}},{"id":2781667,"issuer":{"id":125698,"kind":"organization","name":"Sierra Oncology, Inc.","symbol":"SRRA"},"owners":[{"id":39979,"kind":"person","name":"Jagpal Sukhi","position":1,"cik":"0001554591","reported_name":"Jagpal Sukhi","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-03-17T21:14:56.000Z","date":"2021-03-15","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 25% of the total shares subject to the option on March 15, 2022, and then 2.0833% of the shares subject to the option vest monthly thereafter, with 100% of the total shares subject to the option vested on March 15, 2025, subject to Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":30000,"derivative":{"exercise_price":16.73,"expiration_date":"2031-03-15","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001209191-21-021619","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1290149/000120919121021619/doc4.xml","form_type":"4"}},{"id":3060002,"issuer":{"id":125698,"kind":"organization","name":"Sierra Oncology, Inc.","symbol":"SRRA"},"owners":[{"id":39979,"kind":"person","name":"Jagpal Sukhi","position":1,"cik":"0001554591","reported_name":"Jagpal Sukhi","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2020-08-12T21:36:05.000Z","date":"2020-08-12","kind":"grant","acquired":true,"shares":5887,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 25% of the total shares on August 10, 2021, and then 2.0833% of the total shares vest monthly thereafter, with 100% of the total shares vested on August 10, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":5887,"derivative":{"exercise_price":12.15,"expiration_date":"2030-08-12","underlying":"Common Stock","underlying_shares":5887},"source":{"system":"sec-edgar","filing":"0001209191-20-046501","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1290149/000120919120046501/doc4.xml","form_type":"4"}},{"id":3243607,"issuer":{"id":125698,"kind":"organization","name":"Sierra Oncology, Inc.","symbol":"SRRA"},"owners":[{"id":39979,"kind":"person","name":"Jagpal Sukhi","position":1,"cik":"0001554591","reported_name":"Jagpal Sukhi","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2020-02-27T16:15:08.000Z","date":"2020-02-25","kind":"grant","acquired":true,"shares":94113,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 25% of the total shares on February 25, 2021, and then 2.0833% of the total shares vest monthly thereafter, with 100% of the total shares vested on February 25, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":94113,"derivative":{"exercise_price":13.31,"expiration_date":"2030-02-25","underlying":"Common Stock","underlying_shares":94113},"source":{"system":"sec-edgar","filing":"0001209191-20-013406","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1290149/000120919120013406/doc4.xml","form_type":"4"}},{"id":3611569,"issuer":{"id":125698,"kind":"organization","name":"Sierra Oncology, Inc.","symbol":"SRRA"},"owners":[{"id":39979,"kind":"person","name":"Jagpal Sukhi","position":1,"cik":"0001554591","reported_name":"Jagpal Sukhi","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2019-03-05T17:28:23.000Z","date":"2019-03-04","kind":"grant","acquired":true,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 25% of the total shares on January 1, 2020, and then 2.0833% of the total shares vest monthly thereafter, with 100% of the total shares vested on January 1, 2023, subject to the reporting person's provision of service to the issuer on each vesting date."}],"balance_after":200000,"derivative":{"exercise_price":1.96,"expiration_date":"2029-03-04","underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0001209191-19-016740","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1290149/000120919119016740/doc4.xml","form_type":"4"}},{"id":4007992,"issuer":{"id":125698,"kind":"organization","name":"Sierra Oncology, Inc.","symbol":"SRRA"},"owners":[{"id":39979,"kind":"person","name":"Jagpal Sukhi","position":1,"cik":"0001554591","reported_name":"Jagpal Sukhi","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2018-03-07T17:55:16.000Z","date":"2018-03-06","kind":"grant","acquired":true,"shares":180360,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 25% of the total shares on January 1, 2019, and then 2.0833% of the total shares vest monthly thereafter, with 100% of the total shares vested on January 1, 2022, subject to the reporting person's provision of service to the issuer on each vesting date."}],"balance_after":180360,"derivative":{"exercise_price":2.36,"expiration_date":"2028-03-06","underlying":"Common Stock","underlying_shares":180360},"source":{"system":"sec-edgar","filing":"0001209191-18-017780","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1290149/000120919118017780/doc4.xml","form_type":"4"}},{"id":4394611,"issuer":{"id":125698,"kind":"organization","name":"Sierra Oncology, Inc.","symbol":"SRRA"},"owners":[{"id":39979,"kind":"person","name":"Jagpal Sukhi","position":1,"cik":"0001554591","reported_name":"Jagpal Sukhi","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2017-03-08T17:44:52.000Z","date":"2017-03-06","kind":"grant","acquired":true,"shares":70000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 25% of the total shares on January 1, 2018, and then 2.0833% of the total shares vest monthly thereafter, with 100% of the total shares vested on January 1, 2021, subject to the reporting person's provision of service to the issuer on each vesting date."}],"balance_after":70000,"derivative":{"exercise_price":1.45,"expiration_date":"2027-03-06","underlying":"Common Stock","underlying_shares":70000},"source":{"system":"sec-edgar","filing":"0001209191-17-019362","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1290149/000120919117019362/doc4.xml","form_type":"4"}},{"id":4586594,"issuer":{"id":125698,"kind":"organization","name":"Sierra Oncology, Inc.","symbol":"SRRA"},"owners":[{"id":39979,"kind":"person","name":"Jagpal Sukhi","position":1,"cik":"0001554591","reported_name":"Jagpal Sukhi","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2016-10-04T17:10:15.000Z","date":"2016-09-30","kind":"grant","acquired":true,"shares":168000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 2.7778% of the total shares monthly, beginning on October 30, 2016, with 100% of the total shares vested and exercisable on September 30, 2019, subject to the reporting person's provision of service to the issuer on each vesting date."}],"balance_after":168000,"derivative":{"exercise_price":1.82,"expiration_date":"2026-09-30","underlying":"Common Stock","underlying_shares":168000},"source":{"system":"sec-edgar","filing":"0001209191-16-144436","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1290149/000120919116144436/doc4.xml","form_type":"4"}}]}